CD274 and neoplasm: Although tumor-based PD-L1 expression remains the main immune-based biomarker in clinical practice for the ICI therapy, some patients with high PD-L1 expression do not benefit from ICI treatment as well as patients with low or negative PD-L1 expression, thus supporting the need to identify other reliable biomarkers (9).